| Nov 14 |
Windtree Therapeutics appoints new CEO
|
| Nov 14 |
Windtree Announces Leadership Transition Plan With Industry Veterans
|
| Nov 13 |
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
|
| Nov 4 |
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong
|
| Oct 30 |
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3
|
| Oct 24 |
Windtree Therapeutics completes national phase filings for istaroxime
|
| Oct 23 |
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
|
| Oct 21 |
Windtree To Present at the ThinkEquity Conference on October 30th
|
| Oct 17 |
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
|
| Oct 14 |
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones
|
